|
|
Vaccine Detail
|
MUC1 (Glyco)peptide Vaccine: KLH/MAP-4/chimeric |
| Vaccine Information |
- Vaccine Name: MUC1 (Glyco)peptide Vaccine: KLH/MAP-4/chimeric
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Ding et al., 1993)
- Immunization Route: subcutaneous injection
- Description: A synthetic peptide vaccine targeting the MUC1 mucin core peptide sequence in three configurations with RIBI adjuvant: (1) KLH-conjugated peptides (SP1-7-KLH, SP1-14-KLH with Tn glycosylation), (2) MAP-4 dendritic clustered peptides (SP1-5 with full 20-amino-acid MUC1 tandem repeat; SP1-6 with CST-3 T-helper epitope), and (3) linear chimeric peptides (SP1-16 with tetanus toxin T-helper epitope). Tested in CAF1 mice bearing MUC1-transfected murine mammary adenocarcinoma (E3/410.4 cells), vaccination elicited configuration-dependent responses: SP1-5 induced poor IgG but strong DTH, achieving 52% tumor reduction prophylactically (p<0.03); SP1-7-KLH generated high IgG and DTH with 49-56% tumor reduction (p<0.002). Both significantly prolonged survival therapeutically (p<0.02), with cellular immunity (DTH) driving anti-tumor efficacy over antibody responses. Vaccine-induced IgG cross-reacted with E3 and human MCF-7 breast cancer cells. Vaccines target the immunodominant PDTRP epitope (B-cell epitope in mice; T-cell/CTL epitope in humans). MUC1 is a membrane-bound polymorphic epithelial mucin overexpressed in underglycosylated form in breast, pancreatic, and ovarian cancers, exposing cryptic peptide epitopes (Ding et al., 1993).
|
| Host Response |
|
|
| References |
Ding et al., 1993: Ding L, Lalani EN, Reddish M, Koganty R, Wong T, Samuel J, Yacyshyn MB, Meikle A, Fung PY, Taylor-Papadimitriou J. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer immunology, immunotherapy : CII. 1993; 36(1); 9-17. [PubMed: 8422670].
|
|
